These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18464292)

  • 21. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
    Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
    Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
    Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
    J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma.
    Verhoest G; Patard JJ; Fergelot P; Jouan F; Zerrouki S; Dreano S; Mottier S; Rioux-Leclercq N; Denis MG
    Urol Oncol; 2012; 30(4):469-75. PubMed ID: 20863722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clear cell papillary renal cell carcinoma: a clinicopathological study emphasizing ultrastructural features and cytogenetic heterogeneity.
    Shi SS; Shen Q; Xia QY; Tu P; Shi QL; Zhou XJ; Rao Q
    Int J Clin Exp Pathol; 2013; 6(12):2936-42. PubMed ID: 24294381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.
    Xie J; Zhu C; Wu J; Li C; Luo L; Xia L; Li X; Gui Y; Cai Z; Li Z
    Oncotarget; 2016 Feb; 7(6):6824-34. PubMed ID: 26758419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
    Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
    World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
    Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
    Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
    Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
    Grabmaier K; A de Weijert MC; Verhaegh GW; Schalken JA; Oosterwijk E
    Oncogene; 2004 Jul; 23(33):5624-31. PubMed ID: 15184875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
    Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Masson D; Zerrouki S; Jouan F; Collet N; Dubourg C; Lobel B; Denis M; Fergelot P
    Br J Cancer; 2009 Oct; 101(8):1417-24. PubMed ID: 19755989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
    Büscheck F; Fraune C; Simon R; Kluth M; Hube-Magg C; Möller-Koop C; Shadanpour N; Bannenberg C; Eichelberg C; Höflmayer D; Clauditz T; Wittmer C; Wilczak W; Sauter G; Fisch M; Rink M; Eichenauer T
    Urol Oncol; 2018 Dec; 36(12):531.e19-531.e25. PubMed ID: 30322727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
    Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
    Vlachostergios PJ; Papathanassiou M; Anagnostou M; Thodou E; Tamposis I; Mitrakas L; Zachos I; Koukoulis GK; Samara M; Tzortzis V
    F1000Res; 2023; 12():918. PubMed ID: 38933491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAIX and pax-8 Commonly Immunoreactive in Endolymphatic Sac Tumors: A Clinicopathologic Study of 26 Cases with Differential Considerations for Metastatic Renal Cell Carcinoma in von Hippel-Lindau Patients.
    Thompson LDR; Magliocca KR; Andreasen S; Kiss K; Rooper L; Stelow E; Wenig BM; Bishop JA
    Head Neck Pathol; 2019 Sep; 13(3):355-363. PubMed ID: 30291511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.